文献速递其他结缔组织病

抗Ro52抗体在抗MDA5阳性临床无肌病性皮肌炎合并间质性肺病中的预后价值

Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究纳入83例抗MDA5阳性临床无肌病性皮肌炎合并间质性肺病(CADM-ILD)患者,采用免疫印迹法和光密度半定量检测抗Ro52抗体。结果显示抗Ro52抗体阳性率74.7%,与快速进展型间质性肺病(RP-ILD)和皮肤溃疡频率增加相关,24个月累积生存率有降低趋势;抗MDA5抗体水平与抗Ro52抗体状态联合可进一步分层患者生存率。

要点

  • 抗Ro52抗体在抗MDA5阳性CADM-ILD患者中阳性率74.7%。
  • 抗Ro52抗体与RP-ILD(54.8% vs 23.8%,P=0.014)和皮肤溃疡(27.4% vs 4.8%,P=0.033)相关。
  • 抗MDA5抗体与抗Ro52抗体双阳性者24个月生存率显著低于仅抗MDA5抗体弱阳性者(59.9% vs 100%,P=0.019)。

核心结论

  • 抗Ro52抗体在抗MDA5阳性CADM-ILD患者中高度流行,其与抗MDA5抗体共存提示更侵袭性的临床表型。
  • 抗MDA5抗体水平联合抗Ro52抗体状态有助于预测患者预后并指导基于风险的治疗。

研究设计与样本

  • 研究评估了83例连续入组的抗MDA5阳性CADM-ILD成人患者队列。
  • 抗MDA5抗体和抗Ro52抗体采用免疫印迹法检测,并通过光密度法半定量分析。
  • 比较了抗MDA5阳性患者中伴与不伴抗Ro52抗体的临床特征和24个月生存率。

主要发现

  • 抗Ro52抗体在抗MDA5阳性CADM-ILD患者中阳性率为74.7%。
  • 抗Ro52抗体与RP-ILD频率增加相关(54.8% vs 23.8%;P=0.014)。
  • 抗Ro52抗体与皮肤溃疡频率增加相关(27.4% vs 4.8%;P=0.033)。
  • 伴抗Ro52抗体患者24个月累积生存率较不伴者呈降低趋势(59.9% vs 85.7%;P=0.051)。
  • 抗MDA5抗体与抗Ro52抗体双阳性者生存率显著低于仅抗MDA5抗体弱阳性者(59.9% vs 100%;P=0.019)。

临床怎么用

  • 在抗MDA5阳性CADM-ILD患者中检测抗Ro52抗体有助于识别更侵袭性表型(如RP-ILD和皮肤溃疡风险更高)。
  • 联合抗MDA5抗体水平与抗Ro52抗体状态可辅助预后分层,指导基于风险的治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anti-Ro52 antibody often co-occurs with anti-Jo1 antibody in antisynthetase syndrome and their co-occurrence correlates with a more aggressive clinical phenotype and poorer prognosis. The strong association of anti-Ro52 antibody with anti-melanoma differentiation-associated protein-5 (anti-MDA5) antibody has been indicated in juvenile myositis. The aim of this study was to assess the clinical significance of anti-Ro52 antibody in a cohort of adult patients with anti-MDA5-positive clinically amyopathic dermatomyositis with interstitial lung disease (CADM-ILD). METHODS: We assessed a cohort of 83 consecutive patients with anti-MDA5-positive CADM-ILD. Anti-MDA5 antibodies and anti-Ro52 antibodies were detected in immunoblotting and semi-quantitatively analysed by densitometry. Clinical features and the 24 month survival were compared between anti-MDA5-positive patients with and without anti-Ro52 antibodies. RESULTS: Anti-Ro52 antibodies were found in 74.7% of anti-MDA5-positive CADM-ILD patients and were associated with an increased frequency of rapidly progressive interstitial lung disease (RP-ILD; 54.8% vs 23.8%; P = 0.014) and cutaneous ulcerations (27.4% vs 4.8%; P = 0.033). The cumulative 24 month survival rate tended to be lower in patients with anti-Ro52 antibodies than patients without (59.9% vs 85.7%; P = 0.051). The combination of anti-Ro52 antibody status and anti-MDA5 antibody levels further stratified patients' survival rates, showing that the survival rate of patients who were dual positive for anti-MDA5 antibody and anti-Ro52 antibody was significantly lower than patients with mild positive anti-MDA5 antibody alone (59.9% vs 100%; P = 0.019). CONCLUSION: Anti-Ro52 antibody is highly prevalent in anti-MDA5-positive CADM-ILD patients and their coexistence correlates with a subgroup of patients with more aggressive phenotypes. The combination of anti-MDA5 antibody levels and anti-Ro52 antibody status could help to predict patients' prognosis and guide risk-based therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Xu A, Ye Y, Fu Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021. PMID: 33331866. doi:10.1093/rheumatology/keaa786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。